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The transcriptional regulator RovA positively regulates transcription of the Yersinia enterocolitica virulence gene inv. Invasin,
encoded by inv, is important for establishment of Y. enterocolitica infection. However, a rovA mutant is more attenuated for
virulence than an inv mutant, implying that RovA regulates additional virulence genes. When the Y. enterocolitica RovA regulon
was defined by microarray analysis, YE1984 and YE1985 were among the genes identified as being upregulated by RovA. Since
these genes are homologous to Xenorhabdus nematophila cytotoxin genes xaxA and xaxB, we named them yaxA and yaxB, re-
spectively. In this work, we demonstrate the effects of YaxAB on the course of infection in the murine model. While a yaxAB mu-
tant (yaxAB) is capable of colonizing mice at the same level as the wild type, it slightly delays the course of infection and results
in differing pathology in the spleen. Further, we found that yaxAB encode a probable cytotoxin capable of lysing mammalian
cells, that both YaxA and YaxB are required for cytotoxic activity, and that the two proteins associate. YaxAB-mediated cell death
occurs via osmotic lysis through the formation of distinct membrane pores. In silico tertiary structural analysis identified pre-
dicted structural homology between YaxA and proteins in pore-forming toxin complexes from Bacillus cereus (HBL-B) and
Escherichia coli (HlyE). Thus, it appears that YaxAB function as virulence factors by inducing cell lysis through the formation of
pores in the host cell membrane. This characterization of YaxAB supports the hypothesis that RovA regulates expression of mul-
tiple virulence factors in Y. enterocolitica.
Yersinia enterocolitica is an enteric pathogen causing a range ofdiseases, from mild diarrhea to a more severe systemic bacte-
remia (1, 2). Y. enterocolitica infection typically results in an acute
inflammatory disease of the gastrointestinal tract and/or mesen-
teric lymph nodes and is characterized by diarrhea, fever, and
abdominal pain (1, 2). Normally the infection is cleared in 1 to 2
weeks; however, in some cases, especially when the host is immu-
nocompromised or has high serum iron levels, the infection can
become systemic and mortality rates are high (1, 2). Infection with
Y. enterocolitica most commonly results from consumption of
contaminated food, milk, or water. Livestock populations have
been shown to harbor a high carriage rate of Y. enterocolitica (3, 4),
and it is thought that this Y. enterocolitica burden in the food
supply contributes to human yersiniosis (4).
A number of years ago a murine model of oral infection was
established that mimics human systemic Y. enterocolitica infection
(5, 6). In this model, Y. enterocolitica survives passage through the
stomach, binds to intestinal epithelial cells, and crosses the epithe-
lium, where it colonizes the Peyer’s patches. From here, the bac-
teria can spread to the mesenteric lymph nodes (MLN), spleen,
and liver (6). Mice infected with highly pathogenic biovar 1B
strains develop a lethal systemic infection (3, 6, 7). During a Y.
enterocolitica infection, an inflammatory response from the host
results in an influx of macrophages and neutrophils to the sites of
infection, aided by the production of proinflammatory cytokines,
such as gamma interferon (IFN-), tumor necrosis factor alpha
(TNF-), and interleukin-6 (IL-6) (6, 8–11). This influx of im-
mune cells contributes to the pathology of a Y. enterocolitica in-
fection, and lesions of primarily neutrophils surrounding necrotic
tissue and bacteria have been reported in the MLN, spleens, and
livers of infected mice (6, 10, 12). Similar colonization patterns
and pathology are observed in humans with systemic yersiniosis
(1, 2).
Y. enterocolitica possesses several virulence factors that allow
the bacterium to bind and invade host cells (9, 13, 14). One of
these factors is invasin, an outer membrane protein that binds to
1-integrins on the apical surface of intestinal M cells, aiding the
bacterial translocation across M cells into the Peyer’s patches be-
low (13, 15–17). Our laboratory previously showed that the tran-
scriptional regulator RovA controls expression of inv, the gene
encoding invasin (18). RovA is thermoregulated and is responsi-
ble for the temperature dependence of inv expression in Y. entero-
colitica and Y. pseudotuberculosis (18, 19). Further investigation
into inv regulation revealed that two other regulatory proteins,
H-NS and YmoA, repress inv transcription (18, 20–22). However,
RovA can displace H-NS from the inv promoter (21, 23), suggest-
ing they compete for binding at the inv promoter. YmoA has not
been shown to directly bind the inv promoter, but it has been
shown to negatively regulate inv expression (20, 22). It is thought
that YmoA and H-NS form a repressive complex that binds to the
promoter of inv, and that RovA displaces this complex, acting as a
derepressor to induce transcription of inv (22).
A strain of Y. enterocolitica with a mutation in rovA is less vir-
ulent than an inv mutant, implying that RovA also regulates other
Y. enterocolitica genes important for virulence (18, 24). Compar-
ison of gene expression profiles from the wild type and a rovA
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mutant of Y. enterocolitica using microarray analysis revealed 62
other RovA-regulated genes (25). Two of the genes upregulated in
the presence of RovA, YE1984 and YE1985, are located adjacent to
each other in the Y. enterocolitica chromosome and are predicted
to form an operon (25). These genes are homologous to genes
recently described to encode a two-protein cytotoxin from Xe-
norhabdus nematophila, XaxAB (25, 26). Due to the homology to
xaxAB, we have named YE1984 and YE1985 yaxA and yaxB, re-
spectively. Both RovA and H-NS bind to the predicted promoter
region of yaxA, and RovA, H-NS, and YmoA regulate transcrip-
tion of yaxA (25). These data suggest RovA promotes yaxA tran-
scription while H-NS and YmoA inhibit transcription, similar to
the mechanism of inv regulation, implying that regulation of
RovA and H-NS/YmoA is a global regulatory system used by Y.
enterocolitica (25). Since yaxA and yaxB are homologous to genes
known to encode a toxin and are regulated by the same system that
regulates another defined Y. enterocolitica virulence factor, we in-
vestigated whether yaxA and yaxB play a role in Y. enterocolitica
pathogenesis and their effect on mammalian cells in culture.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Bacterial strains and plasmids
used in this work are listed in Table 1. All cultures of Y. enterocolitica were
grown in LB (1% tryptone, 0.5% yeast extract, 170 mM NaCl; Difco [BD
Biosciences], Bedford, MA) at 26°C. All cultures of Escherichia coli were
grown in LB at 37°C. Antibiotics were added to growth medium as needed
at the following concentrations: nalidixic acid (Nal), 20 g/ml; kanamy-
cin (Kan), 100 g/ml (both from Sigma-Aldrich, St. Louis, MO).
Plasmid and strain construction. All strains and plasmids used in this
study are listed in Table 1, and the primers are listed in Table 2. All DNA
inserted into plasmid vectors was verified by DNA sequencing (Eton Bio-
science, San Diego, CA, or Genewiz, South Plainfield, NJ).
A deletion of the yaxA and yaxB genes was made in Y. enterocolitica
JB580v as previously described (27). Briefly, regions upstream of yaxA and
downstream of yaxB were amplified using primers YE1984/5del1 and
YE1984/5del2 (upstream) or YE1984/5del3 and YE1984/5del4 (down-
stream). The products were digested with SalI and BamHI or BamHI and
NotI (upstream and downstream, respectively), ligated into pSR47S cut
with SalI and NotI, and transformed into S17-1pir. The resulting plas-
mid, pGK501, was introduced into Y. enterocolitica by conjugation to
create strain YVM1334 (yaxAB). Confirmation that the genes were de-
leted was determined by PCR using primers outside the region cloned into
pGK501.
Constructs to express yaxA and yaxB were generated as follows. Prim-
ers Yax004 and Yax005 were used to amplify a fragment that included the
ribosomal binding site (RBS) upstream of yaxA as well as yaxA and yaxB
from chromosomal Y. enterocolitica DNA. This product was digested with
EcoRI and BamHI and ligated into pMWO-034 to generate pNW306. A
C-terminal myc tag was added to yaxA by amplifying the gene with a 5=
primer (Yax004) and a 3= primer that contains the sequence for myc
(Yax009). A C-terminal hemagglutinin (HA) tag was added to yaxB using
a similar strategy. The downstream primer Yax006, which includes the
sequence for an HA tag, was used with primer Yax010 to amplify a product
that contained yaxB-HA. Primer Yax010 also contains sequence for the
TABLE 1 Strains and plasmids used in this work
Strain or plasmid Relevant genotype/phenotypea Source or reference
E. coli
DH5 F 80lacZ M15 (lacZYA-argF)U169 deoP recA1 endA1 hsdR17 (rk
 mk
) Invitrogen
S17-1pir recA thi pro hsdR hsdM	 RP4::2-Tc::Mu::Kan Tn7  pir lysogen, Tpr Strr 61
Y. enterocolitica
JB580v 8081v (r m	 Nalr) serotype O:8, biovar 1B 62
YVM1334 JB580v with deletion of yaxAB This work
MC5 Clinical isolate, biovar 1A Gift from M. Cafferkey
MC7 Clinical isolate, biovar 1A Gift from M. Cafferkey
MC8 Clinical isolate, biovar 1A Gift from M. Cafferkey
WC-A Biovar 1B 63
Y295 Biovar 1B 64
657-83 Reference strain, biovar 1B 65
9291-78 Clinical isolate, biovar 1B 65, 66
2400-87 Biovar 1B 64
MC22 Clinical isolate, biovar 3 67
MC32 Clinical isolate, biovar 3 64, 67
MC33 Clinical isolate, biovar 3 67
MC34 Clinical isolate, biovar 3 67
MC6 Clinical isolate, biovar 4 67
MC28 Clinical isolate, biovar 4 67
MC51 Clinical isolate, biovar 4 64, 67
Plasmids
pSR47S MobRP4 oriR6K cloning vector, Kanr 68
pGK501 yaxA/B deletion in pSR47S, Kanr This work
pMWO-005 Low-copy cloning vector, Kanr 39
pMWO-034 Low-copy cloning vector, Kanr 39
pNW306 yaxA and yaxB coding sequence in pMWO-034, Kanr This work
pNW307 yaxA-myc and yaxB-HA coding sequence in pMWO-034, Kanr This work
pNW311 yaxA-myc coding sequence in pMWO-034, Kanr This work
pNW312 yaxB-HA coding sequence in pMWO-005, Kanr This work
a Tpr, trimethoprim resistant; Strr, streptomycin resistant; Kanr, kanamycin resistant; Nalr, nalidixic acid resistant.
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myc tag, so that the ends of these two fragments are homologous. An
additional overlap PCR, using these two products as the template DNA,
was performed with primers Yax004 and Yax006. The resulting product
contained the RBS upstream of yaxA, yaxA-myc, and yaxB-HA. This
product was digested with EcoRI and BamHI and ligated into pMWO-
034, generating plasmid pNW307. To clone YaxA alone, the sequence of
yaxA-myc was amplified using primers Yax001 and Yax011 from plasmid
pNW307. The resulting PCR product was digested with SalI and EcoRI
and ligated into pMWO-034, producing plasmid pNW311. To clone
yaxB-HA without yaxA, primers Yax013 and MWO-05rev were used to
generate a product that contained the sequence of yaxB and the in-frame
HA tag from plasmid pNW307. The product was digested with SacI and
KpnI and ligated into pMWO-005, generating plasmid pNW312.
Animal infection. All animal experiments were conducted with the
approval of the University of North Carolina IACUC (protocol 11-127.0).
Six- to 8-week-old female BALB/c mice were purchased from Jackson
Laboratory (Bar Harbor, ME) and housed in an approved animal facility
with free access to food and water throughout the experiment. Overnight
cultures of Y. enterocolitica, grown in LB broth at 26°C with aeration, were
normalized to an optical density at 600 nm (OD600) of 3.6 with sterile LB
broth. Mice were infected via oral gavage, delivering 5.5 
 108 to 8.0 
 108
Y. enterocolitica cells in 0.1 ml using a 22-gauge ball-tipped feeding needle.
Mock-infected mice were given 0.1 ml LB via oral gavage. At the indicated
time points, mice were euthanized by CO2 asphyxiation and tissues were
harvested. Tissues were weighed and homogenized in sterile PBS. Serial
dilutions of the tissue homogenates were plated to determine bacterial
load in Peyer’s patches, spleens, livers, and mesenteric lymph nodes
(MLN). Dilutions from Peyer’s patches were plated on Yersinia selective
agar (Difco); all other organs were plated on LB agar containing 20 g/ml
nalidixic acid. Plated dilutions and tissue weight was used to determine
CFU/gram of tissue. Statistical significance was determined by analyzing
the CFU/gram of tissue with a two-tailed Mann-Whitney t test.
Histopathology. Mice were infected as described above. Uninfected
(LB-treated) mice or mice infected for 1, 3, 4, 5, or 6 days were sacrificed
by CO2 asphyxiation. The MLN, spleen, and liver were removed and fixed
in 10% neutral buffered formalin (Sigma-Aldrich) for 24 h. Tissues were
embedded in paraffin, sectioned, and stained with hematoxylin and eosin
(H&E) by the UNC Center for Gastrointestinal Biology and Disease Cell
Services and Histology Core. Lesions of Y. enterocolitica infection in the
spleen were enumerated as follows. A single pathologist (L. B. Borst) eval-
uated samples of approximately equal size in a blinded fashion for micro-
scopic lesions of Y. enterocolitica. Individual foci of inflammation, necro-
sis, and intralesional bacteria, regardless of size, were counted as
individual lesions, and the total number of lesions was determined using
the entire longitudinal section of spleen. Lesions were characterized using
cellular morphology on H&E-stained sections. Inflammatory cell infil-
trates were characterized using cytologic features as follows. Nondegen-
erative neutrophils were identified by segmented or ring-shaped nuclei
with clumped heterochromatin and clear to slightly eosinophilic cyto-
plasm; degenerative neutrophils were identified by swollen hypochro-
matic nuclei, hypersegmented nuclei, and hypereosinophilic or foamy
fragmented cytoplasm; and macrophages were identified by a round to
oval, often eccentrically placed, nucleus and moderate to abundant foamy
pale eosinophilic cytoplasm. Areas of necrosis were identified by homo-
geneous eosinophilic staining with loss of cellular detail mixed with baso-
philic cellular and nuclear debris. The data were analyzed with the Student
t test.
Bacterial lysates. Y. enterocolitica or E. coli strains containing plasmids
that express yaxA (pNW311), yaxB (pNW312), both yaxA and yaxB
(pNW307), or vector (pMWO-034) were grown at 26°C (Y. enterocolitica)
or 37°C (E. coli) overnight. Saturated cultures were subcultured into fresh
media to 0.2 OD600 units/ml. Anhydrous tetracycline (ATc; Sigma-Al-
drich) was added to the growth media at 100 g/ml. After 5 h of growth at
26 or 37°C, induced bacteria were collected by centrifugation at 1,200 
 g
for 10 min. Bacterial pellets were resuspended in 200 mM Tris (pH 8.0),
500 mM NaCl, 18% glycerol, 10 mM EDTA at approximately 40 OD600/
ml. Bacteria were lysed by sonication with 10 5-s bursts, resting on ice
between bursts. Samples were centrifuged (16,000 
 g, 20 min) to clear
the lysates; any remaining bacteria were removed by filtering the lysate
through a 0.2-m filter. Protein concentration was determined using
Bradford reagent (Bio-Rad, Hercules, CA). Lysates were stored at 4°C
with no noticeable loss in toxin activity.
Cell culture. The murine macrophage-like cell line J774.A1 (ATCC
TIB-67) was cultured in Dulbecco’s modified Eagle medium (DMEM;
Gibco [Life Technologies], Carlsbad, CA) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Gibco), 1 mM MEM nonessential
amino acids (Gibco), 1 mM sodium pyruvate (Gibco), and 2 mM L-glu-
tamine (Gibco) at 37°C with 5% CO2. The human monocyte cell line
THP-1 (ATCC TIB-202) was cultured in RPMI 1640 (Gibco) supple-
mented with 10% heat-inactivated FBS, 0.05 M -mercaptoethanol
(Gibco), and 2 mM L-glutamine at 37°C under 5% CO2. To differentiate
THP-1 cells, 200 nM phorbol 12-myristate 13-acetate (PMA; Sigma-Al-
drich) was added to the medium for 72 to 96 h. Medium was replaced with
fresh media lacking PMA, and cells were cultured an additional 3 to 5 days
before being used in assays (28). The human epithelial cell line HEp-2
(ATCC CCL-23) was cultured in MEM (Gibco) supplemented with 10%
heat-inactivated FBS at 37°C under 5% CO2. The human colon epithelial
cell line Caco-2 (ATCC HTB-37) was cultured in MEM supplemented
with 10% heat-inactivated FBS, 1 mM MEM nonessential amino acids,
and 1 mM sodium pyruvate at 37°C under 5% CO2. The hemocyte-like
TABLE 2 Primers used in this work
















a Restriction sites are underlined, and sequences for epitope tags are in boldface.
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Drosophila melanogaster cell line S2 (Invitrogen [Life Technologies],
Carlsbad, CA) was cultured in serum-free Sf-900 II (Gibco) at 26°C in
ambient CO2.
To derive macrophages from murine bone marrow (BMM), nonad-
herent cells from a single-cell suspension of bone marrow harvested from
the femurs and tibia of C57BL/6 mice were cultured in DMEM supple-
mented with 10% heat-inactivated FBS, 1 mM sodium pyruvate, 2 mM
L-glutamine, 50 mM -mercaptoethanol (Gibco), and 40 ng/ml macro-
phage colony-stimulating factor (M-CSF; Peprotech, Rocky Hill, NJ) at
37°C under 5% CO2. Cells were cultured for 7 days before being used in
assays.
Microscopy. Eukaryotic cells were grown on glass poly-D-lysine-
coated coverslips (BD Biosciences), incubated with lysate from bacteria
expressing YaxAB or empty vector, fixed to the glass with 4% paraformal-
dehyde (EMD Millipore, Billerica, MA), and stained with Giemsa stain
(IMEB, Inc., San Marcos, CA). Coverslips were mounted with Cyto-
seal-60 (Richard-Allan Scientific, Kalamazoo, MI). Cells were imaged on
an Olympus BX60 microscope. Images were captured digitally using a
SPOT-RT slider charge-coupled device (CCD) camera (Diagnostic In-
struments, Sterling Heights, MI) and iVision imaging software v.4.0.0
(BioVision Technologies, Exton, PA).
LDH release assay. Lactate dehydrogenase (LDH) released from
mammalian cells was assayed with a CytoTox 96 kit by following the
manufacturer’s protocol (Promega, Madison, WI). Briefly, cells were
seeded into 96-well tissue culture-treated plates approximately 16 h be-
fore the assay. Cell density used for each cell type was determined by
measuring LDH release from Triton X-100-treated cells; the number of
cells that gave at least 2-fold more LDH when treated with Triton X-100
than media were used for assays. Specifically, J774.A1 cells and BMM were
seeded at 2 
 105 cells/ml, THP-1 cells at 2 
 104 cells/ml, HEp-2 cells at
1 
 105cells/ml, and Caco-2 cells at 5 
 104cells/ml. Lysates from the
various bacterial strains were added to wells at the indicated concentra-
tions, which were based on total protein content in the lysate preparation.
Cells were incubated in the presence of lysate for 4 h unless otherwise
indicated. Supernatant from the cells was removed and assayed for the
presence of LDH. The level of LDH in the media from lysate-treated cells
was compared to the level from cells treated with Triton X-100 (assumed
to be 100% cell lysis). Where indicated, cells were preincubated with os-
moprotectants, including glycine (5 mM), sucrose (30 mM), raffinose (30
mM), polyethylene glycol 600 (PEG 600; 30 mM), PEG 1450 (30 mM), or
PEG 3350 (30 mM), for 1 h before the addition of bacterial lysates (29, 30).
Lysis of S2 cells was measured using both the Cytotox 96 kit, as de-
scribed above, and R-Biopharm’s (Darmstadt, Germany) D-lactic acid/L-
lactic acid assay, as previously described (31). For the R-Biopharm kit,
assays were performed in 240-l reaction mixtures with 50 l of culture
supernatant added to each reaction mixture. After reactions were initiated
by the addition of NAD, absorbance at 340 nm was measured using a
BioTek Synergy H1 and Gen5 software (version 1.11; BioTek, Winooski,
VT) every 2 min for 1 h. S2 cells were seeded at 1 
 106 cells/ml approx-
imately 16 h before the assay. Cells treated with Triton X-100 were con-
sidered 100% lysed, and these readings were used as maximum lysis. Bac-
terial lysates were added to cells as described for the mammalian cell
assays. J774.A1 cells were also tested using the R-Biopharm assay and
resulted in similar LDH release, as seen with the Promega kit. Statistical
analysis for all LDH release assays was performed with the two-tailed
Mann-Whitney t test.
Immunoprecipitation and Western blot analysis. Cleared bacterial
lysates, prepared as described above (Y. enterocolitica expressing YaxA,
YaxB, both YaxA and YaxB, or vector), were incubated with mouse an-
ti-HA agarose beads (Sigma-Aldrich) overnight at 4°C. Beads were
washed three times with 200 mM Tris (pH 8.0), 500 mM NaCl, 18%
glycerol, 10 mM EDTA. Following washes, beads were suspended in 1

SDS buffer and boiled. Proteins in lysates and proteins recovered from
anti-HA precipitation were separated by SDS-PAGE and transferred to
Immobilon-P polyvinylidene difluoride (PVDF; EMD Millipore) for
Western blot analysis. Primary antibodies, monoclonal rabbit anti-HA,
and rabbit anti-myc (Cell Signaling Technology, Danvers, MA) were used
at a concentration of 1:2,000, and peroxidase-conjugated secondary anti-
body (Sigma-Aldrich) was used at 1:20,000. A chemiluminescent signal
was generated using ECL plus (GE Healthcare, Piscataway, NJ) or Clarity
Western ECL substrate (Bio-Rad), and emitted light was captured using a
G:Box and GeneSys software (version 1.2.5; Syngene, Frederick, MD).
Y. enterocolitica strain survey for yaxAB. To determine if the se-
quences for yaxAB are present in Y. enterocolitica strains from different
biovars, chromosomal DNA was obtained from the strains listed in Table
1 by phenol-chloroform extraction. Primers were designed using the se-
quence from 8081v (32). The upstream primer (Yax014) (Table 2) binds
yaxA 3= of the start codon, and the downstream primer (Yax015) binds the
3= end of yaxB, including the stop codon. PCR was performed with these
primers using MyTaq DNA polymerase (BioLine USA, Boston, MA) ac-
cording to the supplier’s instructions. The JB580v and yaxAB strains
were used as positive and negative controls, respectively. PCR products
were separated on a 1.5% agarose gel, stained with ethidium bromide, and
visualized using the Syngene G:Box and GeneSys software (version 1.2.5;
Syngene).
YaxA structural prediction and modeling. To identify structural mo-
tifs in YaxA and YaxB, the following algorithms were used to predict protein
motifs and topology: TMpred (ch.embnet.org/software/TMPRED_form
.html), using a window of 17 to 33 amino acids; HMMTOP (enzim.hu.hm-
mtop), which uses a 17- to 25-amino-acid window to predict transmembrane
helices; TMHMM (cbs.dtu.dk/services/TMHMM), which models trans-
membrane helices between 15 and 25 amino acids; and TopPred (http:
//mobyle.pasteur.fr/cgi-bin/portal.py?#forms::toppred), using a window of
21 amino acids (33–36). To identify tertiary structural homology and predict
protein function, the protein sequence was submitted to the Iterative Thread-
ing Assembly Refinement (I-TASSER) server (zhanglab.ccmb.med.umi-
ch.edu/I-TASSER) (37, 38). I-TASSER generated a three-dimensional model
that was viewed and manipulated with PyMOL, version 1.3 (Schrödinger
LLC, Portland, OR).
RESULTS
YaxAB affect the course of murine oral Y. enterocolitica infec-
tion. Our laboratory previously showed that yaxA and yaxB, ho-
mologs to the genes which encode the cytotoxins XaxA and XaxB
(26), are positively regulated by RovA and negatively regulated by
H-NS and YmoA (25). To determine if yaxA and yaxB are impor-
tant in Y. enterocolitica virulence, a strain was constructed with a
complete deletion of yaxAB (the yaxAB mutant). We compared
the course of an oral infection between this mutant strain and
wild-type Y. enterocolitica (JB580v) in BALB/c mice. Both Y. en-
terocolitica strains were able to colonize Peyer’s patches within the
first 24 h following infection (data not shown). At the time points
examined, 1, 3, and 5 days postinoculation (dpi), equal numbers
of CFU were recovered from the Peyer’s patches and mesenteric
lymph nodes (MLN) of mice infected with either the wild-type or
mutant strain (Fig. 1A and data not shown). Likewise, we saw no
significant difference in the rate of bacterial dissemination or col-
onization in the livers of infected mice at 3 and 5 dpi (data not
shown). These data imply that YaxAB does not play a role in the
establishment of Y. enterocolitica infection. However, in the
spleen, there were fewer CFU at 3 dpi in mice infected with
the yaxAB strain (median, 553 CFU/g) than in those infected
with the wild type (median, 1.7 
 106 CFU/g) (Fig. 1B). At 5 dpi,
the difference in bacterial load was reduced (mean, 1.8 
 107
CFU/g in yaxAB mutant-infected mice and 1.4 
 108 CFU/g in
wild type-infected mice) (Fig. 1B). While there are differences in
the splenic bacterial burden between the wild type- and yaxAB
mutant-infected mice, due to the large variation of CFU recovered
Y. enterocolitica Pore-Forming Toxin YaxAB
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from the spleens of mice, the data are not statistically significant
using the Mann-Whitney t test (P  0.285). Along with different
numbers of recovered bacteria from the spleens, we also noticed a
trend of more mice surviving yaxAB mutant infection to day
five. At this time point, 38% of mice infected with the wild-type
strain had succumbed to infection, while only 17% of mice in-
fected with the yaxAB mutant had died.
YaxAB influence host pathology in response to Y. enteroco-
litica. The difference in survival at day 5 between the yaxAB
mutant- and wild type-infected mice caused us to investigate
whether or not a difference exists in pathology between mice in-
fected with these two strains. We found considerable inflamma-
tion in the Peyer’s patches and MLN of mice infected with both
strains at 1 dpi and in the Peyer’s patches, MLN, and spleens at 3
and 5 dpi (data not shown). Lesions consisting of neutrophils
surrounding necrotic areas and apoptotic bodies were previously
reported for Y. enterocolitica infection (10, 11, 24). At 5 dpi, lesions
similar to those previously described and consisting of the same
cell types were seen in the spleens of mice infected with either
strain; however, more lesions were present in the spleens of mice
infected with the mutant strain (mean of 53 lesions per spleen at 5
dpi) than in those infected with wild-type bacteria (mean of 2
lesions per spleen at 5 dpi) or mock infected (no lesions observed)
(Fig. 2). Microscopically, these lesions consisted primarily of de-
generative and nondegenerative neutrophils and fewer macro-
phages, which mix with necrotic cellular debris and apoptotic
bodies (Fig. 2A to D). The inflammatory infiltrates surround vari-
ably large central aggregates of extracellular bacteria (Fig. 2C to E).
The spleens of mice infected with the yaxAB mutant strain of Y.
enterocolitica had fewer bacteria and more lesions than mice in-
fected with the wild-type strain (Fig. 1B and 2F).
Further supporting the idea that yaxAB plays a role in viru-
lence, we found conservation of the yaxAB sequence among
strains of the pathogenic biovars 1B, 3, and 4 and not in strains
from biovar 1A by a PCR screen (data not shown). In every strain
tested from biovars 1B, 3, and 4 (Table 1), a PCR product was
detected using primers flanking yaxAB in strain 8081v (primers
Yax014 and Yax015) (Table 2). As these genes have been main-
tained in pathogenic strains of Y. enterocolitica, particularly in the
highly pathogenic 1B strains, it would seem that the proteins pro-
vide some advantage. While the impact on the murine model of
systemic infection was modest, YaxAB could play a more signifi-
cant role in other mammalian infections, including humans. Al-
ternatively, YaxAB may be important for establishing and/or
maintaining a Y. enterocolitica reservoir.
YaxAB are cytotoxic in vitro. Since YaxAB are homologous to
a defined cytotoxin (XaxAB), we wanted to determine if YaxAB
had similar properties. The expression of yaxA and yaxB under
normal laboratory growth conditions is undetectable (25); there-
fore, in order to produce YaxAB, we induced expression of yaxA
and yaxB. The genes encoding YaxA and YaxB were cloned into
pMWO-034, a low-copy-number expression vector with an anhy-
drous tetracycline (ATc)-inducible promoter (39). The yax genes
were cloned in tandem, either directly from the chromosomal
DNA (pNW306) or with C-terminal epitope tags (YaxA-myc and
YaxB-HA; pNW307), and transformed into wild-type Y. enteroco-
litica. Bacterial lysates were prepared by sonication from mid-log
cultures that had been grown with ATc and were used to treat
tissue culture cells (YaxAB lysate). Once we established activity in
lysates prepared from pNW306 (untagged), we confirmed equal
activity in the tagged version of the proteins (pNW307). For the
reported experiments, YaxAB lysates were generated from
pNW307 so that expression could be verified by visualizing the
epitope tags. When J774.A1 murine macrophage-like cells were
incubated with YaxAB lysate, destruction of the cells was evident
within 4 h by microscopy and LDH release (Fig. 3A and B). Cells
incubated with lysate from bacteria harboring pMWO-034 (vec-
tor lysate) (Fig. 3B, samples V) showed the same level of LDH
release as untreated cells (Fig. 3B, samples U), indicating that these
lysates had low or no cytotoxic activity. To ensure native yaxAB
expression did not contribute to toxicity, vector lysates were pre-
pared from both wild-type and yaxAB strains and were found to
have equally low levels of LDH release (data not shown).
To determine if YaxAB-mediated killing was specific to
J774.A1 cells, we incubated other cell types with these same lysates
(Fig. 3B, samples Y). YaxAB lysates induced statistically significant
LDH release in murine bone marrow-derived macrophages
(BMM; 100% maximum), human monocytes derived from
THP-1 cells (74.0% maximum), the human epithelial cell line
HEp-2 (22.6% maximum), and Caco-2 human colon epithelial
cells (35.2% maximum) compared to cells left untreated or treated
with vector lysate (Fig. 3B, samples U or V, respectively). Because
XaxAB was shown to be an insect toxin, we also tested for YaxAB
toxicity on the Drosophila melanogaster phagocytic hemocyte cell
line S2. We observed no difference in cell death by LDH release or
microscopy between S2 cells incubated with YaxAB lysate or vec-
FIG 1 Colonization of BALB/c mice infected intragastrically with Y. enteroco-
litica. Mice were infected with 5.5 
 108 to 8 
 108 CFU of the wild-type ()
or yaxAB (Œ) strain. At the indicated time points, animals were sacrificed and
tissues were harvested to determine the colonization of the mesenteric lymph
nodes (A) or spleen (B). Each symbol represents one mouse, an X indicates a
dead mouse, black bars are the median numbers of CFU recovered per gram of
tissue, and dashed lines are set at the limit of detection. Data are from three
independent experiments.
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FIG 2 Infection with the yaxAB mutant results in more splenic lesions than wild-type infection. Shown are H&E-stained splenic sections from a mouse infected
with either the wild-type (A) or yaxAB (B to D) strain. (A and B) The image at 
2 magnification. Lesions with similar appearance and cellular makeup are
present throughout both spleens (examples are highlighted by arrows); however, more lesions are apparent in the yaxAB mutant-infected spleen (B). The region
shown in the black box of panel B is enlarged in panel C. (C) The image at 
10 magnification. The region shown in the box is enlarged in panel D. (D) The image
at 
60 magnification. The large colonies of bacteria are identified with an arrowhead and are surrounded by numerous neutrophils (identified by segmented or
ring-shaped nuclei) and fewer macrophages (identified by round or oval nuclei and abundant foamy cytoplasm). Apoptotic bodies were occasionally observed
(arrow). (E) Splenic lesion boxed in panel B stained with anti-Yersinia antibody (brown) showing bacteria localized within the splenic lesions of yaxAB
mutant-infected mice. Magnification, 
10. (F) Splenic lesions were counted per spleen in wild-type-infected (), yaxAB mutant-infected (Œ), or mock-
infected (not shown) mice. The number of lesions per spleen is shown. Each symbol represents one mouse, and black bars represent the means. At 5 dpi, there
are significantly more lesions per spleen in yaxAB mutant-infected mice than wild-type-infected mice, as determined by one-sample t test.
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tor lysate (data not shown). Together, these data suggest that Y.
enterocolitica YaxAB is cytotoxic to mammalian cells but not in-
sect cells, and that there is a more potent effect on immune cell
lines.
YaxAB-mediated toxicity acts through osmotic lysis. As we
had established that YaxAB was toxic to mammalian cells, we
wanted to investigate the mechanism by which YaxAB causes cell
death. Since YaxAB-mediated killing of J774.A1 cells is robust, this
cell line was chosen for further investigation. We tested the ability
of YaxAB-containing bacterial lysates to induce LDH release from
J774.A1 cells over time and found that YaxAB-induced permeabi-
lization of J774.A1 cells can be detected by LDH release as early as
20 min after addition of YaxAB lysate (Fig. 3C), a time point when
cells show no gross sign of lysis via microscopy (data not shown).
Levels of LDH release increased with time, and maximal levels
were observed within 1 h of YaxAB lysate exposure (Fig. 3C). Low
levels of LDH were detected from cells treated with vector lysate
and remained at baseline throughout the time course tested (5 to
10% of maximum) (Fig. 3C). Similar results were seen when ly-
sates were incubated with bone marrow-derived macrophages
(data not shown).
The time-course LDH release assay indicates that the mecha-
nism of YaxAB-mediated killing is fast acting, with complete lysis
of J774.A1 cells within 1 h. One phenomenon that can cause rapid
cell death is osmotic lysis. To test if this was the mechanism by
which YaxAB acted on J774.A1 cells, cells were preincubated for 1
h prior to the addition of YaxAB lysate with glycine, which non-
specifically blocks osmotic lysis by preventing ion flux across cell
membranes (30, 40–42). Glycine protected J774.A1 cells from
YaxAB-mediated lysis, as the treated cells displayed LDH release at
levels similar to those from cells treated with vector lysates (25.6%
compared to 18.7% of the maximum) (Fig. 3D). These data imply
that YaxAB is killing target cells through osmotic lysis. While the
osmotic protection provided by glycine is not pore size specific,
other molecules that do not impact ion flux will block osmotic
lysis when the molecules are larger than the pore size, whereas
particles smaller than the pore should freely pass through and the
cell will still be subject to lysis (30, 43, 44). To test whether or not
exposure to YaxAB resulted in the formation of pores and to esti-
mate the pore size, cells were pretreated with molecules of various
sizes (sucrose, 0.9 nm; raffinose, 1.1 nm; PEG 600, 2.0 nm; PEG
1450, 2.4 nm; PEG 3350, 3.8 nm) (29, 30) for 1 h, followed by
lysate treatment and LDH release assay. Pretreatment with PEG
1450 or PEG 3350 conferred the same protection as that observed
with glycine, producing low LDH release levels (37.6 and 14.4% of
maximum, respectively) (Fig. 3D). However, sucrose, raffinose,
and PEG 600 did not confer any protection to J774.A1 cells from
YaxAB-mediated killing. These data indicate that YaxAB form a
distinct pore in the target cell membrane, and that the pore size is
between 2.0 and 2.4 nm.
Pore-forming toxins can induce K	 flux, leading to capsase-1
activation and cell death (45, 46). Additionally, cells that have
activated the NLRP3/caspase-1-mediated cell death pathway also
have distinct pores formed in the membrane (30, 41). To deter-
mine if the rapid osmotic lysis we see in target cells involves the
caspase-1-mediated cell death pathway(s) (pyrotosis), we tested
the ability of YaxAB to kill macrophages derived from the bone
marrow of caspase-1/ mice. Immortalized caspase-1/ bone
marrow-derived macrophages (a gift from Edward Miao) had el-
evated levels of LDH release when exposed to YaxAB lysate (76.5%
FIG 3 YaxAB kills mammalian cells by osmotic lysis. (A) Light microscopy
images (
20) of Giemsa-stained J774.A1 cells exposed to YaxAB lysate for 4 h.
(B to D) LDH measured from culture supernatants and represented as a per-
centage of Triton X-100-treated cells (maximal lysis control). (B) LDH re-
leased from the indicated cells after a 4-h incubation with PBS (untreated [U]),
vector lysate (V), or YaxAB lysate (Y). (C) LDH released from J774.A1 cells
treated with vector lysate (, dashed line) or YaxAB lysate (Œ, solid line). (D)
LDH release from J774.A1 cells after 1 h of preincubation with the indicated
osmoprotectants, followed by 1 h of incubation with vector or YaxAB lysate. In
panels B to D, means  SEM are shown. *, P  0.05; **, P  0.005; ***, P 
0.0001; ns, not significant.
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of maximum) compared to those exposed to vector lysate (47.7%
of maximum) or untreated cells (44.4% of maximum) (data not
shown). Therefore, YaxAB-mediated cell death occurs in a
caspase-1-independent manner. From these data, we conclude
that YaxAB-mediated cell death occurs through caspase-1-inde-
pendent osmotic lysis by the formation of discrete membrane
pores.
Toxicity requires both YaxA and YaxB. To determine whether
both YaxA and YaxB are required for toxicity, constructs were
generated that expressed epitope-tagged versions of either YaxA
or YaxB (plasmid pNW311 expresses YaxA-myc and pNW312
expresses YaxB-HA). These plasmids were transformed into wild-
type Y. enterocolitica, and YaxA or YaxB expression was confirmed
by Western blotting (Fig. 4A). Lysates from bacteria expressing
YaxA-myc (YaxA lysate), YaxB-HA (YaxB lysate), or both YaxA-
myc and YaxB-HA (YaxAB lysate) were generated as described
above and incubated with J774.A1 cells. When lysates from bacte-
ria expressing either component individually were incubated with
cells, the amount of LDH released into the medium was compa-
rable to levels in cells treated with vector lysate (YaxA lysate,
28.1% of maximum; YaxB lysate, 26.5% of maximum; vector ly-
sate, 27.5% of maximum) (Fig. 4B). When YaxA lysate was added
to cells, followed 1 h later by YaxB lysate, J774.A1 cells released
near-maximal LDH levels (67.2%) (Fig. 4B), demonstrating that
both YaxA and YaxB are required for YaxAB-mediated toxicity.
Interestingly, when lysate from bacteria expressing YaxB was
added to J774.A1 cells prior to the addition of YaxA lysate, there
was minimal LDH release (37.1% of maximum) (Fig. 4B). Similar
results were reported with XaxA and XaxB from Xenorhabdus
(26, 30).
Since both proteins are required for toxic activity, it was of
interest to determine whether YaxA and YaxB directly interact.
Lysates from bacteria expressing both YaxA-myc and YaxB-HA
were incubated with anti-HA antibody bound to agarose beads.
After incubation, the beads were washed, boiled in SDS loading
buffer, run on an SDS-PAGE gel, and Western blotted with an
anti-HA antibody to confirm that YaxB was pulled down and an
anti-myc antibody to assay for coimmunoprecipitation (Fig. 4C).
A positive HA signal from samples containing YaxB-HA (Fig. 4C,
samples AB) showed that the immunoprecipitation worked as ex-
pected. A positive myc signal from the anti-HA beads indicated
that the antibody on the beads pulled down YaxA-myc with YaxB-
HA. Fractions eluted from anti-HA beads incubated with lysate
from bacteria expressing only YaxA-myc did not react with either
the anti-HA or the anti-myc antibody by Western blotting (Fig.
4C, samples A), indicating that YaxA detected from YaxAB lysate
is the result of interactions between YaxB and YaxA, not nonspe-
cific binding of YaxA to the anti-HA agarose beads. These data
confirm that YaxA and YaxB directly interact.
Predicted structure of YaxA homologous to pore-forming
toxin. Our data established that YaxAB induces lysis of target cells
by forming pores in the target cell membrane. Further supporting
the idea that YaxAB is a cytolysin, the sequence of YaxA has struc-
tural homology to known pore-forming toxins. The amino acid
sequence of YaxA was analyzed with the iterative threading assem-
bly refinement (I-TASSER) server, which derived a predicted
model of YaxA. This model had a confidence score (C-score) of
1.4. The C-score estimates the quality of the model based on the
significance of threading template alignments and convergence of
the I-TASSER structural assembly refinements (37). At least 90%
of the predictions are accurate when models have C-scores of
greater than 1.5 (37). As part of the I-TASSER analysis, TM-
align was used to compare the predicted structure of YaxA to
crystallized proteins with similar structures. TM-align identified
one component of a three-protein Bacillus cereus toxin, HblB
(PDB code 2NRJ), and the E. coli toxin HlyE (also called ClyA and
SheA) (PDB code 1QOY) as highly similar to the predicted struc-
ture of YaxA. Using the structures of these toxins, TM-align gen-
erated overlays of the predicted structure of YaxA with HblB and
YaxA with HlyE (Fig. 5). Examination of these overlays shows that
the structure of YaxA predicted by I-TASSER is highly similar to
the structure of HlyE, but it has a stronger alignment with HblB
(root mean square deviation [RMSD] of 1.24 and 4.31, respec-
tively). YaxA structure prediction based on HblB orients it with
five long coils and a head region extending from one side (Fig. 5).
In HblB, this head is predicted to contain a transmembrane do-
main that may insert into the membrane of the target cell (47).
The head of HlyE has been shown to undergo a conformational
change upon membrane association, causing this region of the
protein to swing away from the rest of the protein and into the
FIG 4 Both YaxA and YaxB are required for lysis and are copurified. (A)
Western blot of YaxA-myc and YaxB-HA from bacteria expressing both YaxA
and YaxB (AB) or YaxA (A) or YaxB (B) alone. Anti-HA and anti-myc anti-
bodies were used to verify YaxA-myc and YaxB-HA expression. (B) LDH mea-
sured from culture supernatants and represented as a percentage of Triton
X-100-treated cells. LDH release from J774.A1 cells after 1 h of incubation with
vector (V), YaxAB lysate (AB), YaxA lysate (A), or YaxB lysate (B), 1 h of
incubation with YaxA lysate followed by 1 h with YaxB lysate (A¡B), or 1 h of
incubation with YaxB lysate followed by YaxA lysate for 1 h (B¡A). Means 
SEM are shown. **, P  0.005. (C) YaxAB (AB) or YaxA (A) lysates were
incubated with agarose beads bound with anti-HA antibody. The supernatant
was removed and the beads were washed three times. The washed beads and
starting lysate were analyzed by Western blotting as described above.
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membrane of a target cell (48). Motif prediction algorithms (TM-
pred, TopPred, HMMTOP, and TMHMM; see Materials and
Methods for details) suggest that the portion of YaxA that aligns
with the head region of HblB also contains a transmembrane do-
main, and the function of this region may be similar to that of this
region of HblB and HlyE.
DISCUSSION
Here, we demonstrate that the RovA-regulated genes yaxAB en-
code proteins which contribute to cytotoxic activity for both hu-
man and murine cells in culture. We also demonstrate that
YaxAB-mediated toxicity acts through the formation of pores in
the membrane of target cells, causing osmotic lysis that can be
blocked by osmoprotectants. YaxAB plays a role in the pathoge-
nicity of Y. enterocolitica, as the absence of these genes results in
altered pathology and lower levels of bacterial colonization of the
spleen. The structural homology of YaxA to components of other
pore-forming toxins is especially intriguing, as this mechanism of
cytotoxicity appears to be conserved across many bacterial species.
Along with the structural similarity, hlyE and yaxAB are both reg-
ulated by similar mechanisms involving the homologous proteins
SlyA (E. coli) and RovA (Y. enterocolitica) in relieving H-NS-me-
diated repression (25, 49, 50).
The predicted structural homology of YaxA to the known
pore-forming toxins HblB and HlyE supports our data that YaxAB
forms pores in the membranes of host target cells. Like YaxAB,
HlyE is toxic to macrophage-like cells in culture, and it has been
shown to lyse cells via osmotic lysis (51, 52). Additionally, the
pores YaxAB and HlyE form in the membrane of target cells are of
similar sizes (HlyE pores are 2.5 to 3.0 nm, and YaxAB pores are
2.0 to 2.4 nm) (50–54). While the structural models do not fit
between HlyE and YaxA as well as those between HblB and YaxA
(Fig. 5), the regulatory and functional similarities between HlyE
and YaxA are intriguing and hint at a global mechanism for toxin
production and function in these two enteric pathogens.
Curiously, we found no structural or sequence homolog for
YaxB other than the previously described XaxB-like proteins in
Xenorhabdus and Photorhabdus (26), indicating that its role in the
toxicity mechanism is unique to this group of proteins. Our data
show that YaxA alone has no cytotoxic activity. HblB also requires
other proteins for function (HblL1 and HblL2), but HlyE is toxic
without any other proteins (51, 52, 55). This suggests that while
there are structural similarities among YaxA, HblB, and HlyE, the
YaxAB toxin complex employs a mechanism of toxicity distinct
from those of these other two pore-forming toxins. It is interesting
that when the proteins were expressed separately, we found full
lytic activity only occurred when YaxA was added before YaxB.
Similar results were reported for the Xenorhabdus XaxAB and Ba-
cillus HBL toxin complexes (26, 55). Thus, it seems likely that the
pore-forming portion of each of these toxins acts similarly upon
the host cell, but the mechanism of toxicity and/or how the target
cell is exposed to the toxin varies between bacterial species. There
is some evidence that XaxB, as well as XaxA, can bind membrane
(26), so one explanation for these results is that addition of XaxB
(or YaxB) prior to XaxA (or YaxA) leads to membrane binding in
a manner that is no longer competent for interaction with the
corresponding A component.
The method of release from the bacteria or surface exposure
utilized by YaxAB has not been determined, as is the case for the
structural homolog, HlyE. There is no evidence that HlyE is se-
FIG 5 Structural comparisons of YaxA to HblB and HlyE. (A) I-TASSER structural prediction of YaxA based on tertiary alignment with HblB. The predicted
transmembrane domain is shown in pink. (B) Predicted structure of YaxA (blue and pink) overlaid on the crystal structure of HblB (green). (C) Predicted
structure of YaxA overlaid on the crystal structure of HlyE (red).
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creted through any of the type I to V secretion systems, and it does
not contain any described signal sequences or appear to have any
signal sequence cleavage or posttranscriptional modifications (50,
56). YaxA and YaxB also contain no defined signal sequence and
were not secreted from Y. enterocolitica under any of the condi-
tions tested (N. J. Wagner & V. L. Miller, unpublished data). It is
possible that YaxA and YaxB are released spontaneously as a result
of bacterial lysis, or that they are released from the bacteria
through outer membrane vesicles, as has been suggested for HlyE
(56). However, we were unable to detect YaxAB-mediated cell
death using live bacteria (N. J. Wagner and V. L. Miller, unpub-
lished).
In this work, the source of YaxAB for in vitro studies was de-
rived from bacterial lysates made from Y. enterocolitica induced to
express yaxAB. The plasmid we used to express yaxAB has a very
low copy number (approximately 5 plasmids per bacterium [39,
57, 58]), but as we induced gene expression, the levels of protein
likely were higher than what is produced from the chromosomal
copy of the genes. Therefore, assays performed with induced
yaxAB may overstate the impact of these genes in the native bac-
terium. Additionally, as our experiments were carried out using
bacterial lysates as the source of YaxAB, it is conceivable that some
other bacterial component acts in conjunction with YaxAB as part
of the toxin complex. Attempts to purify YaxA and YaxB to con-
firm their toxicity were unsuccessful. While our data show that
YaxAB have toxic effects, until the purified proteins can be tested,
we cannot definitively state that Yax-mediated cytotoxicity is due
solely to the presence of YaxAB.
Along with questions about optimal expression of native
yaxAB and how YaxAB is released from the bacteria, it remains to
be determined how the YaxAB toxin binds to target cells. Since
more complete death of macrophage-like cells is observed com-
pared to that of epithelial cells, it may be that the target/receptor of
YaxAB is expressed on most or all macrophage (or hematopoietic)
cells while it is present in only a subset of cultured epithelial cells.
Alternatively, YaxAB could bind nonspecifically to host cells via a
universal cell component, such as cholesterol. In support of this
idea, the E. coli toxin HlyE binds cholesterol and is thought to
target cells for lysis through this interaction (52). Identifying the
binding target on host cells will contribute to our understanding
of how YaxAB influences virulence; the identity of the receptor
may determine if the effect of YaxAB is focused only on immune
cells or if it may equally impact other cell types in vivo.
Mice infected with the yaxAB mutant have fewer CFU/gram
in the spleen than mice infected with the wild type, yet more le-
sions are found in the spleens of mice infected with the yaxAB
mutant. While these phenotypes are subtle, they suggest that the
absence of YaxAB alters the immune response to Y. enterocolitica.
Since YaxAB is an apparent cytotoxin, the presence of YaxAB
could result in the death of cells recruited to the site of infection,
thereby altering the immune response of the host in order to fa-
cilitate bacterial survival. This may lead to changes in cytokine
expression in the spleens of mice infected with yaxAB strains
compared to those infected with wild-type Y. enterocolitica. We
attempted to determine if gross changes in cytokine response were
occurring in the spleens of mice infected with the wild-type or
yaxAB mutant Y. enterocolitica strain by testing for IL-6 and
IFN- by ELISA. We found that the results from splenic homog-
enates varied greatly (N. J. Wagner and V. L. Miller, unpublished).
With the wide range of cytokine concentrations measured, we did
not detect significant differences in these cytokines. It is possible
that while there was no change in cytokine levels at the whole-
spleen level, the difference in cellular localization seen in the
yaxAB mutant-infected spleens results in an altered localized
cytokine response. These localized changes could lead to differen-
tial cellular recruitment of immune cells to sites of infection,
which may explain the increased number of splenic lesions seen in
mice infected with the yaxAB mutant. More sensitive techniques
to measure local cytokine levels would need to be employed to
determine if these differences are occurring in wild-type and
yaxAB mutant-infected spleens. In addition to alterations in cell
recruitment, the recruited cells could be responding differently to
the mutant bacteria. It has been shown that when mice depleted of
dendritic cells are infected with Y. enterocolitica, the neutrophil
response is altered such that a greater number of neutrophils are
recruited to sites of infection (59). Additionally, infected mice
depleted of dendritic cells generate more reactive oxygen species
(ROS) (both total and per cell) (59). If YaxAB-mediated cell death
results in a reduction in the number of dendritic cells and/or mac-
rophages, the immune response could be similarly altered.
While we observed that the course of yaxAB strain infection is
altered from that of wild-type Y. enterocolitica, neither the inv
nor the yaxAB strain shows the level of attenuation of the rovA
mutant strain (17, 18, 60). The yaxAB strain shows a defect in
colonization of the spleen, and the inv strain exhibits delayed
colonization of the Peyer’s patches (9); however, colonization of
the mesenteric lymph nodes was equal between mice infected with
wild-type Y. enterocolitica or either of these mutant strains (9)
(Fig. 1). This is in contrast to reports of defective colonization of
the Peyer’s patches, spleen, and mesenteric lymph nodes by the
rovA mutant. Additionally, we did not observe the reduced Peyer’s
patch inflammation in mice infected with the yaxAB strain that
has been reported with the rovA mutant strain (18). These data
suggest that while the impact of RovA on virulence of Y. enteroco-
litica depends on yaxAB and inv, neither the inv nor the yaxAB
mutant shows the colonization defect in the MLN that is apparent
in the rovA mutant. Although it is possible a more severe defect
would be apparent in a strain with both mutations, the data from
the three single-mutant strains (rovA, inv, and yaxAB) imply that
additional RovA-regulated genes contribute to pathogenicity.
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